J Rheum Dis.  2019 Jul;26(3):179-185. 10.4078/jrd.2019.26.3.179.

Nonsteroidal Anti-inflammatory Drugs-sparing Effect of Symptomatic Slow-acting Drugs for Osteoarthritis in Knee Osteoarthritis Patients

• Cho SK
• Kim H
• Park HR
• Choi W
• Choi S
• Jung SY
• Jang EJ
• Sung YK

• KMID: 2451509
• DOI: http://doi.org/10.4078/jrd.2019.26.3.179

Abstract

OBJECTIVE
To evaluate the nonsteroidal anti-inflammatory drugs (NSAID)-sparing effect of symptomatic slow-acting drugs for osteoarthritis (SYSADOA) in knee osteoarthritis (OA) patients.
METHODS
A retrospective study was conducted on a cohort of knee OA patients who visited a single academic referral hospital from 2013 to 2014. Among all patients, NSAID users in their first visit were extracted and divided into SYSADOA users and SYSADOA non-users. All patients were observed from their first visit with knee OA to their last visit, NSAID discontinuation, or the date of data collection, July 2017 (mean observational periods: 369.1 days). To evaluate the NSAID-sparing effect of SYSADOA, Cox regression analysis was performed after adjusting for confounding factors.
RESULTS
Patients for this study (n=212) were divided into SYSADOA users (n=57) and SYSADOA non-users (n=155). The mean age (68.8 vs. 66.6 years old, p=0.31) and the number of comorbidities (p=0.73) were comparable between the two groups. The SYSADOA users showed higher Kellgren-Lawrence (KL) grade (66.7% of patients with more than KL grade 3) than SYSADOA non-users (42.6% of patients with more than KL grade 3) (p=0.02). In treatment, the frequency of intra-articular injection was higher in the SYSADOA user group than the SYSADOA non-user group (33.3% vs. 9.0%, p<0.01). In Cox regression analysis, SYSADOA use contributed to NSAID discontinuation in knee OA patients (hazard ratio 2.97, 95% confidential interval 1.42∼6.22).
CONCLUSION
This real-world analysis demonstrated that SYSADOA use combined with NSAIDs had a significant effect on NSAID discontinuation in patients with knee OA.

Keyword

Osteoarthritis; Symptomatic slow-acting drugs for osteoarthritis; Nonsteroidal anti-inflammatory drugs

MeSH Terms

Anti-Inflammatory Agents, Non-Steroidal
Cohort Studies
Comorbidity
Data Collection
Humans
Injections, Intra-Articular
Knee*
Osteoarthritis*
Osteoarthritis, Knee*
Referral and Consultation
Retrospective Studies
Anti-Inflammatory Agents, Non-Steroidal

Reference

1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003; 81:646–56.

2. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet. 2012; 380:2197–223.

3. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis. 2001; 60:91–7.

4. Kim I, Kim HA, Seo YI, Song YW, Jeong JY, Kim DH. The prevalence of knee osteoarthritis in elderly community residents in Korea. J Korean Med Sci. 2010; 25:293–8.

5. Park JH, Hong JY, Han K, Suh SW, Park SY, Yang JH, et al. Prevalence of symptomatic hip, knee, and spine osteoarthritis nationwide health survey analysis of an elderly Korean population. Medicine (Baltimore). 2017; 96:e6372.

6. Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013; 21:571–6.

7. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012; 64:465–74.

8. National Clinical Guideline Centre (UK). Osteoarthritis: care and management in adults. London: National Institute for Health and Care Excellence (UK);2014.

9. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014; 22:363–88.

10. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62:1145–55.

11. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340:1888–99.

12. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382:769–79.

13. Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996; 23:1385–91.

14. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006; 354:795–808.

15. Hochberg MC, Martel-Pelletier J, Monfort J, Möller I, Castillo JR, Arden N, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75:37–44.

16. Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. Int J Rheum Dis. 2012; 15:69–77.

17. Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S. Thai Study Group. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, dou-ble-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007; 15:605–14.

18. Rovati LC, Girolami F, D'Amato M, Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal antiinflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016; 45(4 Suppl):S34–41.

19. Park HR, Cho SK, Im SG, Jung SY, Kim D, Jang EJ, et al. Treatment patterns of knee osteoarthritis patients in Korea. Korean J Intern Med. 2018 Mar 21; [Epub].DOI: DOI:10.3904/kjim.2017.304.

20. Lapane KL, Liu SH, Dubé CE, Driban JB, McAlindon TE, Eaton CB. Factors associated with the use of hyaluronic acid and corticosteroid injections among patients with radiographically confirmed knee osteoarthritis: a retrospective data analysis. Clin Ther. 2017; 39:347–58.

21. Wilson N, Sanchez-Riera L, Morros R, Diez-Perez A, Javaid MK, Cooper C, et al. Drug utilization in patients with OA: a population-based study. Rheumatology (Oxford). 2015; 54:860–7.

22. Seo HJ, Sung YK, Choi CB, Lee EB, Cheong C, Kim SY, et al. Prevalence and factors affecting glucosamine use in Korea: a survey-based study. Rheumatol Int. 2013; 33:1627–31.

23. Hartog A, Hougee S, Faber J, Sanders A, Zuurman C, Smit HF, et al. The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators. Phytomedicine. 2008; 15:313–20.

24. Yoo WH, Yoo HG, Park SH, Baek HJ, Lee YJ, Shim SC, et al. Efficacy and safety of PG201 (Layla^Ⓡ) and celecoxib in the treatment of symptomatic knee osteoarthritis: a dou-ble-blinded, randomized, multicenter, active drug comparative, parallel-group, non-inferiority, phase III study. Rheumatol Int. 2014; 34:1369–78.

25. Lee SY, Kwon HK, Lee SM. SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: first therapeutic application for the treatment of osteoarthritis. Arch Pharm Res. 2011; 34:1773–7.

26. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, et al. Genomewide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013; 9:e1003394.

27. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage. 1998; 6:427–34.

28. Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol. 1998; 25:2417–24.

29. Shin SS, Jin M, Jung HJ, Kim B, Jeon H, Choi JJ, et al. Suppressive effects of PG201, an ethanol extract from herbs, on collagen-induced arthritis in mice. Rheumatology (Oxford). 2003; 42:665–72.